Company Profile

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

25-04-09	OS Therapies Finalizes Acquisition of Advaxis Assets From Ayala Pharmaceuticals	MT
25-04-08	OS Therapies Incorporated completed the acquisition of Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc..	CI
25-01-29	OS Therapies to Acquire Certain Ayala Pharmaceuticals Assets	MT
25-01-28	OS Therapies Incorporated agreed to acquire Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Inc. for $8 million.	CI
24-04-16	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-15	Ayala Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-04-15	Ayala Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-03	Ayala Pharmaceuticals, Inc. Announces Departure of Roy Golan as Chief Financial Officer, Effective from June 25, 2024	CI
24-04-03	Andres Guttierez, Chief Medical Officer and Executive Vice President, Departs from Ayala Pharmaceuticals, Inc	CI
24-03-24	Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	CI
24-02-20	Ayala Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 3 Ringside Study Evaluating AL102 in Desmoid Tumors	CI
24-02-06	Top Midday Gainers	MT
24-02-06	Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	MT

24-05-09	Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations	AQ
24-03-26	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	AQ
24-02-20	Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	AQ
24-02-06	Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals	AQ
23-11-06	Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors	AQ

Manager	Title	Age	Since
Ken Berlin CEO	Chief Executive Officer	61	2018-03-31
Oren Elmaliach AUD	Comptroller/Controller/Auditor	42	2022-01-31

Director	Title	Age	Since
Ken Berlin BRD	Director/Board Member	61	2018-03-31
David Sidransky CHM	Chairman	66	2017-10-31
Robert Spiegel BRD	Director/Board Member	76	2022-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/1/24	Israel Biotech Fund	Exercice	Company	15,000,000	35.1837%
2/7/24	Israel Biotech Fund	Exercice	Company	60,988,804	-
11/17/23	Israel Biotech Fund	Buy	Company	42,112,500	-

Ayala Pharmaceuticals, Inc. Stock

Stocks

ADXS

US0076244062

Biotechnology & Medical Research

Chart: Ayala Pharmaceuticals, Inc.

Latest news: Ayala Pharmaceuticals, Inc.

Analysts' recommendations: Ayala Pharmaceuticals, Inc.

Press Releases: Ayala Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Ayala Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AYALA PHARMACEUTICALS, INC.	+5.89%	+25.22%	-	-	35.79M
LONZA GROUP AG	+0.11%	+2.71%	+0.44%	+23.80%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+29.70%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+542.28%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+81.93%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.57%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+140.41%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.19%	+36.16%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-0.45%	+3.76%	+53.72%	+127.98%	29.15B
Weighted average by Cap.	-1.10%	+1.87%	+68.04%	+137.66%